光學基因組圖譜市場－全球產業規模、佔有率、趨勢、機會及預測（按產品、應用、最終用戶、地區和競爭格局分類，2021-2031年）

全球光學基因組圖譜市場預計將從 2025 年的 2.7 億美元成長到 2031 年的 9.7 億美元，複合年成長率為 23.76%。

光學基因組圖譜技術是一種非定序技術，它分析極長的DNA分子，以超越傳統細胞遺傳學方法的解析度檢測結構變異。該市場的主要促進因素是臨床上對骨髓惡性腫瘤精準診斷日益成長的需求，以及實驗室向整合各種傳統工作流程的數位化檢測方法的策略轉型。這些因素使醫療機構能夠更有效率地產生全面的基因組圖譜，從而改善患者照護並縮短獲得重要診斷結果的時間。

儘管臨床獲益顯著，但設備的巨額初始投資以及分析所需的大量生物資訊資源，對小規模病理中心而言，是推廣應用該技術的重大障礙。歐洲血液學會2024年發表的數據顯示，與標準通訊協定相比，採用光學基因組圖譜的臨床研究可使約18%的髓系腫瘤病例的風險分層得到改善。這項數據固然反映了該平台的診斷優勢，但也凸顯了高階數據解讀的必要性，這可能會減緩其在更廣泛的市場成長。

市場促進因素

光學基因組圖譜技術在癌症診斷和腫瘤監測領域的應用不斷拓展，尤其是在骨髓惡性腫瘤，正從根本上改變全球光學基因組圖譜市場。隨著臨床醫生日益尋求詳細的基因組圖譜以指南精準醫療，拓展光學基因組圖譜技術的功能，使其超越傳統技術的簡單一致性，成為關鍵目標。該技術能夠識別次世代定序常常遺漏的隱匿性結構突變，從而為複雜的白血病和淋巴瘤病例提供重要的預後資訊，因此正迅速得到廣泛應用。美國國家醫學圖書館於2025年4月引用的一項研究表明，與標準細胞遺傳學評估相比，光學基因組圖譜技術在15%的骨髓惡性腫瘤病例中檢測到額外的具有臨床意義的一級突變，這凸顯了其在改善患者管理方面的關鍵作用。

推動市場擴張的第二個主要因素是傳統細胞遺傳學方法（例如核型分析和螢光原位雜合反應(FISH)）的系統性替代品。實驗室正積極將分散的工作流程整合到單一的高解析度數位檢測中，從而提高操作效率並降低與手動方法相關的成本。這種從類比細胞遺傳學轉變為數位細胞遺傳學的比例得益於檢測耗材需求的成長。 2025年1月，Bionano Genomics公司報告稱，2024年第四季奈米通道陣列流動池的銷量為8,058個。此外，同月發布的初步報告顯示，全球光學基因組作圖系統的部署量已增加至371套，顯示實驗室正在持續轉型為此平台。

市場挑戰

光學基因組圖譜技術廣泛應用的主要障礙在於儀器設備的巨額資本投入，以及數據分析所需的大規模生物資訊資源。許多診斷實驗室，尤其是小規模區域中心，面臨嚴重的預算限制，難以承擔高昂的初始硬體成本和持續的專用數位基礎設施維護費用。因此，這種經濟負擔使得該技術的應用主要局限於資金雄厚的學術機構和大規模參考實驗室，難以實現基於大檢體量的商業化市場規模。

這些經濟和技術挑戰的影響體現在近期的市場普及率數據中。根據美國病理學家協會 (CAP) 2024 年的調查數據，僅有 9.4% 的參與實驗室成功實施了光學基因組圖譜技術。如此低的普及率表明，市場仍然高度分散，大多數病理服務機構無法將平台整合到其日常工作流程中。因此，高進入門檻直接限制了全球市場的收入成長潛力，使這項技術局限於小眾領域，而無法擴展到常規臨床實踐中。

市場趨勢

光學基因組圖譜技術在發現未確診的罕見遺傳疾病方面正發揮著重要作用，彌補了傳統疾病標準治療方法的局限性。臨床醫師正積極採用這項技術，在進行EXOME或基因測序後仍未確診的患者中發現致病性結構變異，從而逐步縮短診斷流程。該平台作為生殖系分析的主要工具，其應用範圍正從腫瘤學擴展到醫學遺傳學領域，在醫學遺傳學中，檢測隱匿突變至關重要。根據美國國家醫學圖書館引用的2025年11月報告《光學基因組圖譜技術的現況與未來應用》，調查數據顯示，108家實驗室計畫在24個月內將此技術應用於臨床試驗，這主要是由於其在先天性疾病和生殖系突變分析方面的效用。

同時，將光學基因組圖譜技術引入產前和產後生殖檢測領域，正開闢新的市場商業性途徑。各實驗室正在檢驗該平台在識別胎兒樣本和胚胎著床前胚胎中的平衡易位和複雜染色體重排方面的有效性，其解析度優於染色體微陣列技術。這項技術對於提高體外受精（IVF）的成功率和準確評估復發性流產的風險至關重要，並推動了癌症診斷以外其他領域的成長。 Bionano Genomics公司於2025年3月發布的《2024年第四季及全年財務報告》特別強調了該應用日益成長的科學支持。報告顯示，2024年光學基因組圖譜相關論文總數達336篇，較上年增加19%。這一成長主要得益於產前和產後遺傳疾病研究的顯著進展。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球光學基因組圖譜市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品分類（耗材與設備）
  • 依應用領域（基因組組裝、結構變異檢測、微生物菌株分型、單倍型分析等）
  • 按最終用戶（研究/學術機構、生物技術/製藥公司、臨床檢查室、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美光學基因組圖譜市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲光學基因組圖譜市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區光學基因組圖譜市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲光學基因組圖譜市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美光學基因組圖譜市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球光學基因組圖譜市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Bionano Genomics, Inc.
• Nucleome Informatics Private Limited
• Nabsys, Inc.
• PerkinElmer, Inc.
• SourceBio International Limited
• MedGenome Labs Private Limited
• Cerba HealthCare
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Oxford Nanopore Technologies plc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Optical Genome Mapping Market is projected to expand from USD 0.27 Billion in 2025 to USD 0.97 Billion by 2031, registering a CAGR of 23.76%. As a non-sequencing technology, optical genome mapping analyzes ultra-long DNA molecules to detect structural variations with a resolution exceeding traditional cytogenetic techniques. The market is primarily driven by the rising clinical need for accurate diagnosis of hematologic malignancies and a strategic shift within laboratories to merge various legacy workflows into a unified digital assay. These drivers enable medical facilities to generate comprehensive genomic profiles more efficiently, improving patient care and shortening the time required for critical diagnostic results.

Despite its evident clinical benefits, the substantial initial capital investment for equipment and the considerable bioinformatic resources needed for analysis pose significant hurdles to adoption in smaller pathology centers. Data presented by the European Hematology Association in 2024 revealed that clinical research using optical genome mapping improved risk stratification in roughly 18 percent of myeloid neoplasm cases compared to standard protocols. While this figure highlights the platform's diagnostic advantages, it also emphasizes the sophisticated data interpretation requirements that could slow down broader market growth.

Market Driver

Expanding applications in cancer diagnostics and oncology research, particularly for hematological malignancies, are fundamentally transforming the Global Optical Genome Mapping Market. As clinicians increasingly demand detailed genomic profiles to inform precision medicine, extending the capabilities of optical genome mapping beyond mere agreement with legacy techniques has become a key objective. The technology is rapidly being adopted for its capacity to identify hidden structural variants often overlooked by next-generation sequencing, providing vital prognostic information for complex cases of leukemia and lymphoma. According to a study referenced by the National Library of Medicine in April 2025, optical genome mapping detected additional clinically significant Tier 1 variants in 15 percent of hematological malignancy cases compared to standard cytogenetic evaluations, confirming its critical role in enhancing patient management.

A second major factor propelling market momentum is the systematic replacement of traditional cytogenetic methods like karyotyping and fluorescence in situ hybridization (FISH). Laboratories are actively merging fragmented workflows into this single, high-resolution digital assay to boost operational efficiency and alleviate the cost pressures of labor-intensive manual techniques. This shift from analog to digital cytogenetics is underscored by the rising demand for testing consumables; Bionano Genomics reported in January 2025 the sale of 8,058 nanochannel array flowcells for the fourth quarter of 2024. Furthermore, the company's preliminary report from the same month indicated that the global installed base had grown to 371 optical genome mapping systems, reflecting the increasing operational transition toward this platform.

Market Challenge

The significant capital investment required for instrumentation, coupled with the extensive bioinformatic resources necessary for data analysis, serves as a major obstacle to the widespread uptake of optical genome mapping. Many diagnostic laboratories, particularly smaller community centers, face strict budget limitations that make it difficult to justify the high upfront hardware costs and the continuous expense of specialized digital infrastructure. Consequently, this financial strain limits the technology's availability primarily to well-resourced academic institutions and large reference laboratories, hindering the market from achieving commercial scale based on high sample volumes.

The effect of these economic and technical challenges is reflected in recent adoption figures. Survey data from the College of American Pathologists in 2024 revealed that only 9.4 percent of participating laboratories had successfully integrated optical genome mapping. This low rate of utilization demonstrates that the market remains highly fragmented, with most pathology providers unable to incorporate the platform into their regular workflows. As a result, high entry barriers directly constrain the potential revenue expansion of the global market by relegating the technology to a niche role rather than enabling its progression into routine clinical practice.

Market Trends

A pivotal trend is the application of optical genome mapping to resolve undiagnosed rare genetic diseases, addressing the shortcomings of standard-of-care methods for constitutional disorders. Clinicians are increasingly adopting this technology to uncover pathogenic structural variants in patients who remain without a diagnosis following exome or genome sequencing, thereby concluding distinct diagnostic odysseys. This transition toward utilizing the platform as a primary instrument for germline analysis is extending its reach beyond oncology into medical genetics departments, where detecting cryptic variants is essential. According to the 'Current and Future Utilization of Optical Genome Mapping' report cited by the National Library of Medicine in November 2025, survey data showed that 108 laboratories intend to adopt the technology clinically within 24 months, largely driven by its utility in constitutional and germline analysis.

Simultaneously, the introduction of optical genome mapping into prenatal and postnatal reproductive testing is creating a new commercial pathway for the market. Laboratories are validating the platform to identify balanced translocations and complex chromosomal rearrangements in fetal samples and preimplantation embryos, offering resolution superior to that of chromosomal microarrays. This capability is vital for enhancing in-vitro fertilization success rates and providing precise risk assessments for recurrent pregnancy loss, fueling growth in a segment distinct from cancer diagnostics. The increasing scientific support for this application is highlighted by Bionano Genomics' 'Fourth Quarter and Full-Year 2024 Results' from March 2025, which noted that the total number of optical genome mapping publications rose to 336 in 2024, a 19 percent annual increase characterized by significant research growth in prenatal and postnatal genetic disorders.

Key Market Players

• Bionano Genomics, Inc.
• Nucleome Informatics Private Limited
• Nabsys, Inc.
• PerkinElmer, Inc.
• SourceBio International Limited
• MedGenome Labs Private Limited
• Cerba HealthCare
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Oxford Nanopore Technologies plc

Report Scope

In this report, the Global Optical Genome Mapping Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Optical Genome Mapping Market, By Product

• Consumables v/s Instruments

Optical Genome Mapping Market, By Application

• Genome Assembly
• Structural Variation Detection
• Microbial Strain Typing
• Haplotype Phasing
• Others

Optical Genome Mapping Market, By End User

• Research and Academic Institutions
• Biotechnology & Pharmaceutical Companies
• Clinical Laboratories
• Others

Optical Genome Mapping Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Optical Genome Mapping Market.

Available Customizations:

Global Optical Genome Mapping Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Optical Genome Mapping Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Consumables v/s Instruments)
  • 5.2.2. By Application (Genome Assembly, Structural Variation Detection, Microbial Strain Typing, Haplotype Phasing, Others)
  • 5.2.3. By End User (Research and Academic Institutions, Biotechnology & Pharmaceutical Companies, Clinical Laboratories, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Optical Genome Mapping Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Optical Genome Mapping Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Optical Genome Mapping Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Optical Genome Mapping Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Optical Genome Mapping Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Optical Genome Mapping Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Optical Genome Mapping Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Optical Genome Mapping Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Optical Genome Mapping Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Optical Genome Mapping Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Optical Genome Mapping Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Optical Genome Mapping Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Optical Genome Mapping Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Optical Genome Mapping Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Optical Genome Mapping Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Optical Genome Mapping Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Optical Genome Mapping Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Optical Genome Mapping Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Optical Genome Mapping Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Optical Genome Mapping Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Optical Genome Mapping Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Optical Genome Mapping Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Optical Genome Mapping Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Optical Genome Mapping Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Optical Genome Mapping Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bionano Genomics, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Nucleome Informatics Private Limited
• 15.3. Nabsys, Inc.
• 15.4. PerkinElmer, Inc.
• 15.5. SourceBio International Limited
• 15.6. MedGenome Labs Private Limited
• 15.7. Cerba HealthCare
• 15.8. Illumina, Inc.
• 15.9. Thermo Fisher Scientific Inc.
• 15.10. Oxford Nanopore Technologies plc

16. Strategic Recommendations

17. About Us & Disclaimer